[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519359":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":54,"centralContacts":58,"locations":64,"responsibleParty":79,"collaborators":81,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":36,"eligibilityCriteria":90,"healthyVolunteers":87,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":36,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":36,"overallStatus":67,"whyStopped":36,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Yale University","OTHER",[8,16,21,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Ultrasound during a hyperinsulinemic euglycemic clamp (HEC).","EXPERIMENTAL","Hepatic ultrasound during a hyperinsulinemic euglycemic clamp (HEC).",[13,14,15],"Device: Ultrasound","Diagnostic Test: CGM glucose reading","Diagnostic Test: HEC - Hyperinsulinemic-Euglycemic-Clamp",{"label":17,"type":10,"description":18,"interventionNames":19},"Cohort 2: Ultrasound then NMR with unlabeled glucose.","Hepatic ultrasound and subsequent NMR measurement of glycogen with unlabeled glucose.",[13,20,14],"Diagnostic Test: OGTT with unlabeled glucose and liver NMR",{"label":22,"type":10,"description":23,"interventionNames":24},"Cohort 3: Ultrasound then NMR with carbon13 labeled glucose.","Hepatic ultrasound and subsequent NMR measurement of glycogen with carbon13 labeled glucose.",[13,25,14],"Diagnostic Test: OGTT with carbon-13 labeled glucose and liver NMR",{"label":27,"type":10,"description":28,"interventionNames":29},"Cohort 4: Dual site ultrasound stimulation followed by CGM glucose recording alone.","Hepatoportal plexus + superior mesenteric plexus dual site ultrasound stimulation followed by CGM glucose recording alone.",[13,14],[31,37,42,46,50],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DEVICE","Ultrasound","The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.",[9,17,22,27],null,{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":36},"DIAGNOSTIC_TEST","OGTT with unlabeled glucose and liver NMR","Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.",[17],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":36},"OGTT with carbon-13 labeled glucose and liver NMR","Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.",[22],{"type":38,"name":47,"description":48,"armGroupLabels":49,"otherNames":36},"CGM glucose reading","A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.",[9,17,22,27],{"type":38,"name":51,"description":52,"armGroupLabels":53,"otherNames":36},"HEC - Hyperinsulinemic-Euglycemic-Clamp","A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.",[9],[55],{"name":56,"affiliation":5,"role":57},"Raimund Herzog, MD, MHS","PRINCIPAL_INVESTIGATOR",[59],{"name":60,"role":61,"phone":62,"phoneExt":36,"email":63},"Raimund Herzog, MD MHS","CONTACT","+1 (203) 737-4773","raimund.herzog@yale.edu",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":36},"Yale School of Medicine","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-72.92816,41.30815,{"lat":77,"lon":76},{"type":80,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[82],{"name":83,"class":84},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100519359","mechanisms-of-ultrasound-neuromodulation-effects-in-diabetes-100519359",false,"NCT06042517","Mechanisms of Ultrasound Neuromodulation Effects in Diabetes","Inclusion Criteria:\n\n* Type 2 diabetic (T2D) subjects must be aged 18-80 and must be able to provide written informed consent\n* All subjects must have had T2D for at least 3 months prior to study enrollment. All subjects must be either on diet and exercise or oral antidiabetic agents alone, not on insulin or any form of insulin or GLP-1 receptor agonists.\n* Subjects must demonstrate:\n\n  1. A past medical history of abnormal glucose control and carry a diagnosis of T2D according to current ADA criteria:\n\n     * A fasting plasma glucose (FPG) level of 126 mg\u002FdL (7.0 mmol\u002FL) or higher, or\n     * A 2-hour plasma glucose level of 200 mg\u002FdL (11.1 mmol\u002FL) or higher during a 75-g oral glucose tolerance test (OGTT), or\n     * A random plasma glucose of 200 mg\u002FdL (11.1 mmol\u002FL) or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis or\n     * A hemoglobin A1c (HbA1c) level of 6.5% or higher.\n  2. Be willing to carry a continuous glucose monitor for at least 10 days.\n  3. Be willing to follow all required instructions by study personnel and appear for the required laboratory assessments, including euglycemic clamps and OGTT.\n\nExclusion Criteria:\n\n* BMI \\>40kg\u002Fm2.\n* Untreated proliferative retinopathy\n* Creatinine clearance \\\u003C 60 ml\u002Fmin\u002F1.73 m2.\n* Serum creatinine ≥1.5 mg\u002FdL\n* Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures\n* Active infection including hepatitis C, hepatitis B, HIV,\n* Any history of Active alcohol abuse\n* History of non-adherence to prescribed regimens\n* Baseline Hgb \\\u003C 10.5 g\u002FdL in females, or \\\u003C 13 g\u002FdL in males\n* History of coagulopathy or medical condition requiring long-term anticoagulant therapy (low-dose aspirin treatment is allowed)\n* Co-existing cardiac disease with active medication titration. Patients on stable meds without active cardiac complications permitted.\n* Liver function tests outside of 3xUL of normal range\n* GI disorders potentially interfering with the ability to absorb oral medications and h\u002Fo upper GI surgery that might have changed anatomy in the target areas.\n* Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes.","ALL","18 Years","80 Years",{"count":95,"type":96},77,"ESTIMATED","INTERVENTIONAL",[99],"NA","This study aims to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp).",[102],"Insulin Sensitivity","2025-05-05",{"date":105,"type":106},"2025-05-08","ACTUAL",{"date":108,"type":106},"2023-09-30",{"date":110,"type":96},"2027-09-30",{"name":5,"class":6},1]